01引 言 在提供食欲信号的营养刺激胰腺和肠道激素中,类胰高血糖素样肽-1 (GLP-1) 起到了重要作用。最初用于治疗2型糖尿病(T2D)的GLP-1受体激动剂(GLP-1 RA)由于其胃肠激素效应而成为高效的肥胖治疗药物。GLP-1 RA可以作为单药治疗,也可以与其他基于激素的药物联合使用,作为双重或三重受体激动剂。 过往药物...
exenatideGLP-1liraglutidetaspoglutidetype 2 diabetes mellitusobesityThe glucagon-like peptide-1 (GLP-1) agonist drugs have attractions as a treatment for type 2 diabetes since they positively alter a number of key pathophysiological defects. These include increasing insulin release, reducing glucagon rel...
1. Login or Register with R&D Systems to submit a review 2. Fill out the product review form 3. You will be emailed your reward within 2 weeks email address/username * Enter your www.rndsystems.com username. password * Sign up for a R&D Systems account Register Terms and Conditions...
In recent years, an increased focus has been placed on incretin hormones, such as glucagon-like peptide-1 (GLP-1) for its glucose-lowering benefits. Several FDA-approved short-acting and long-acting GLP-1 receptor agonists (GLP-1 RAs) are available in the United States for the treatment ...
[2] Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy. N Engl J Med. 2010 Mar 4;362(9):774-7. doi: 10.1056/NEJMp1001578. Epub 2010 Feb 17. PMID: 20164475.
[6]EMA Statement on Ongoing Review of GLP-1 Receptor Agonists (EMA, 2023) [7]Chiappini, S. et al. Is there a risk for semaglutide misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) pharmacovigilance dataset. Pharmaceuticals 16, 994 (2023). ...
[5] Tilinca, M. et al. A 2021 update on the use of liraglutide in the modern treatment of ‘Diabesity’: A narrative review. Medicina (Kaunas). 2021, 57, 669. [6] Brown, E. et al. Newer GLP-1 receptor agonists and obesity-diabetes. Peptides. 2018, 100, 61-67. ...
6.Hosie, R. Top gastroenterologists gave a glowing review of new weight loss drugs, and ranked them in order of effectiveness. 20. 10. 2022.7.Rahhal, N. 'Everybody is on it': A 'game-changing' weight-loss drug is NYC's hottest new trend. Business Insider. 11. 04. 2023.8.Terhune...
肥胖药物现已成为新药研发领域的重要方向之一。其中,胰高血糖素样肽1(GLP-1)受体激动剂类药物因出色的临床数据和疗效已成为肥胖新药研发领域的焦点。在今年1月全球知名科技媒体《麻省理工科技评论》(MIT Technology Review)公布的2024年“全球十大突破性技术”中,GLP-1受体激动剂类减肥疗法成功上榜。
[4] Shi Q, Wang Y, Hao Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials[J]. The Lancet, 2022, 399(10321): 259-269.[5] Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide ...